News

This week, April FDA roundup, ESCMID conference coverage, enhancing C difficile treatment, and more from Contagion.

Despite no reported cases of illness associated with the affected products, all retailers who received these items have been duly informed, and the recall is being conducted in coordination with the FDA.

Hospital grades released by Leapfrog reviews state and now metro areas for safety and patient satisfaction.

Detection of E coli bacteria and inorganic arsenic in these products raises significant health concerns.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.

Study reveals concerning trends from the mosquito-borne disease impacting Canada and the US.

A Centers for Disease Control and Prevention (CDC) investigator offers insights into their investigation of customers receiving vampire facials (a spa cosmetic procedure) and contracting the virus afterwards.

The INSPIRE trials find prompts within computerized provider ordering improves antibiotic utilization for pneumonia and urinary tract infections.

Insights from Dr. Md Zahidul Alam on treatments and prevention strategies for C difficile infection (CDI), supported by the CDC's recent study on CDI management in healthcare settings.

A study underscores the microbial etiology of septic arthritis, which can guide clinicians in minimizing the use of overly broad empiric antibiotics.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

Check out the latest studies, management strategies, patient advocacy, and other important news involving this condition.

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

A study presented at ESCMID aims to understand ribotype 955 as a new challenge in C difficile management.

This cephalosporin antibiotic was examined against colistin-susceptible gram-negative infections.

C-SMART trial results presented at ESCMID show a reduction of COVID-19 incidence in cancer patients.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

A novel approach using this emerging technology looks to interfere with antibiotic resistance expression and reduce this global health issue.

Insights into host-directed therapies (HDT) for tuberculosis (TB) gaining traction among experts aiming to combat the disease's various forms, including drug-resistant strains.

A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.

Public health alert over ground beef, FDA approves antibiotics for female adults with uncomplicated UTI, The NYC Department of Health and Mental Hygiene reports a record amount of Leptospirosis cases, and more this week from Contagion.

New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.

Insights from Pranay Sinna MD on a multicenter prospective cohort study on household contacts.

Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.

In a collaboration between the University of Oxford, the Ministry of Health in Rwanda, and the Rwanda Biomedical Centre, groundbreaking data on the R21/Matrix-M malaria vaccine, marks a significant shift in the malaria paradigm.

PEN-FAST is a validated risk stratification tool that promotes efficient, safe, and effective de-labeling of penicillin allergies.

Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her expert insights into this zoonotic disease.